Capsaicin

Generic Name: Capsaicin

Brand Names: Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₇NO_₃

CAS Number: 404-86-4

Unique Ingredient Identifier: S07O44R1ZM

Background: Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Indication: The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.

Associated Conditions: Back Pain Lower Back, Back pain, Bursitis, Contusions, Inflammatory Reaction caused by Rheumatism, Muscle Cramps, Musculoskeletal Pain, Neuropathic Pain, Osteoarthritis (OA), Pain caused by Rheumatism, Periarthritis, Soft Tissue Injury, Tendinitis, Acute nonspecific tenosynovitis, Articular inflammation

Clinical Trials

Capsaicin for Cerebral Perfusion Augmentation.

Phase 1

Completed

Conditions: Stroke

Interventions: Drug: Capsaicin

First Posted Date: 2020-09-11

Last Posted Date: 2020-09-11

Lead Sponsor: Juan Manuel Marquez Romero

Target Recruit Count: 30

Registration Number: NCT04545892

Locations: 🇲🇽
Unidad de Medicina de Alta Especialidad en Torre Médica CMQ, Aguascalientes, Ags., Mexico

The Effect of Capsaicin-induced Pain on Homeostatic Plasticity in Healthy Human Participants

Not Applicable

Conditions: Healthy

Interventions: Drug: Capsaicin Topical - alone
Drug: Placebo - alone
Drug: Capsaicin Topical - ice
Drug: Placebo - ice

First Posted Date: 2020-07-24

Last Posted Date: 2020-08-31

Lead Sponsor: Aalborg University

Target Recruit Count: 24

Registration Number: NCT04485689

Locations: 🇩🇰
Aalborg University, Aalborg, Denmark

Capsaicin for Post-stroke Dysphagia

Phase 2

Recruiting

Conditions: Dysphagia, Late Effect of Stroke

Interventions: Drug: Capsaicin 1% oral solution
Drug: InOrpha Solution

First Posted Date: 2020-07-14

Last Posted Date: 2023-06-22

Lead Sponsor: Georg Kägi, MD

Target Recruit Count: 82

Registration Number: NCT04470752

Locations: 🇨🇭
Kantonsspital St. Gallen, St. Gallen, Saint Gallen, Switzerland

CBD-Microglia PET Study

Early Phase 1

Recruiting

Conditions: Healthy
CBD

Interventions: Radiation: [11C]PBR28
Drug: Low-dose lipopolysaccharide
Drug: Intradermal Capsaicin

First Posted Date: 2020-05-21

Last Posted Date: 2024-08-15

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT04398719

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Motor Unit Abnormalities After Experimentally Induced Sensitization

Phase 4

Completed

Conditions: Central Sensitisation
Motor Disorders

Interventions: Drug: Capsaicin Topical Cream (0.075%)
Device: Delsys Trigno Galileo System
Device: Excaliber, Natus Medical
Other: Placebo Cream

First Posted Date: 2020-04-24

Last Posted Date: 2020-04-24

Lead Sponsor: Toronto Rehabilitation Institute

Target Recruit Count: 23

Registration Number: NCT04361149

Locations: 🇨🇦
Toronto Rehabilitation Institute, Toronto, Ontario, Canada

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

Phase 4

Completed

Conditions: Cannabinoid Hyperemesis Syndrome

Interventions: Drug: Placebo
Drug: Capsaicin

First Posted Date: 2020-02-25

Last Posted Date: 2024-10-18

Lead Sponsor: University of Virginia

Target Recruit Count: 20

Registration Number: NCT04283292

Locations: 🇺🇸
UVA Health System, Charlottesville, Virginia, United States

The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy

Phase 4

Completed

Conditions: Diabetic Neuropathy
Diabetic Complications Neurological
Diabetic Nerve Problems

Interventions: Drug: Lidocaine 5% patch
Drug: Capsaicin 8% Patch, Per 10 Square Centimeters

First Posted Date: 2020-01-23

Last Posted Date: 2020-01-30

Lead Sponsor: Corporacion Parc Tauli

Target Recruit Count: 290

Registration Number: NCT04238208

Locations: 🇵🇰
Zainab Khan, Lahore, Punjab, Pakistan

Quantitative Ultrasound Response of Capsaicin

Early Phase 1

Completed

Conditions: Central Sensitisation

Interventions: Device: Delsys Trigno Galileo System
Drug: Capsaicin
Device: Cadwell Sierra Wave
Device: Sonosite Ultrasound Machine
Device: Goniometer